ZAMMIT, VALENTINA
 Distribuzione geografica
Continente #
EU - Europa 47
NA - Nord America 13
AF - Africa 11
AS - Asia 6
Totale 77
Nazione #
FR - Francia 19
IT - Italia 19
US - Stati Uniti d'America 12
CI - Costa d'Avorio 11
IE - Irlanda 6
PH - Filippine 2
VN - Vietnam 2
CN - Cina 1
DE - Germania 1
HK - Hong Kong 1
MX - Messico 1
NL - Olanda 1
PL - Polonia 1
Totale 77
Città #
Abidjan 11
Ashburn 6
Dublin 6
Catania 5
Belpasso 3
Bacolod City 2
Boardman 2
Dong Ket 2
Paris 2
Rome 2
Bremen 1
Cuauhtemoc 1
Nuoro 1
Piraino 1
Sorso 1
Totale 46
Nome #
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report, file dfe4d22b-886e-bb0a-e053-d805fe0a78d9 25
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22), file dfe4d22b-dbce-bb0a-e053-d805fe0a78d9 16
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib, file dfe4d22c-1ae9-bb0a-e053-d805fe0a78d9 16
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors, file dfe4d22b-5af8-bb0a-e053-d805fe0a78d9 13
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study, file 11cbfe60-66d2-4c84-8347-5b2a4fb2c08f 5
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report, file dfe4d22c-1787-bb0a-e053-d805fe0a78d9 2
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report, file dfe4d22b-dbcc-bb0a-e053-d805fe0a78d9 1
Totale 78
Categoria #
all - tutte 316
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 316


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201 0 0 0 0 0 0 0 0 0 0 0 1
2020/20218 0 3 0 0 0 2 1 0 0 0 0 2
2021/20222 0 0 1 1 0 0 0 0 0 0 0 0
2022/202320 0 0 0 2 1 5 0 0 2 1 9 0
2023/202447 0 11 3 0 2 16 6 7 1 1 0 0
Totale 78